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ARTICLE
Crossing the blood-brain-barrier with nanoligand
drug carriers self-assembled from a phage display
peptide
Lin-Ping Wu 1*, Davoud Ahmadvand2,8, Junan Su3, Arnaldur Hall4, Xiaolong Tan5, Z. Shadi Farhangrazi6 &
S. Moein Moghimi 2,5,7,9*
The filamentous bacteriophage fd bind a cell target with exquisite specificity through its few
copies of display peptides, whereas nanoparticles functionalized with hundreds to thousands
of synthetically generated phage display peptides exhibit variable and often-weak target
binding. We hypothesise that some phage peptides in a hierarchical structure rather than in
monomeric form recognise and bind their target. Here we show hierarchial forms of a brain-
specific phage-derived peptide (herein as NanoLigand Carriers, NLCs) target cerebral
endothelial cells through transferrin receptor and the receptor for advanced glycation-end
products, cross the blood-brain-barrier and reach neurons and microglial cells. Through
intravenous delivery of NLC-β-secretase 1 (BACE1) siRNA complexes we show effective
BACE1 down-regulation in the brain without toxicity and inflammation. Therefore, NLCs act
as safe multifunctional nanocarriers, overcome efficacy and specificity limitations in active
targeting with nanoparticles bearing phage display peptides or cell-penetrating peptides and
expand the receptor repertoire of the display peptide.
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Nanoparticulate drug carriers are receiving considerableattention for site-specific targeting of diagnostic andtherapeutic agents for detection, monitoring and treat-
ment of various diseases1. A dominant strategy in targeting with
drug carriers is their surface functionalisation with a wide range
of target-specific ligands (e.g., folate, antibodies and their frag-
ments, proteins such as transferrin and a plethora of designer
peptides), a process often referred to as “active targeting”2–4.
The phage display technology is a valuable tool in identification
of numerous peptide ligands for active targeting5–10. Here the
library of foreign peptide or protein variants is displayed as
expression of the fusions to the bacteriophage coat protein (e.g.,
the p3 protein on the bacteriophage fd) and each variant is shown
on the surface of a virion5. On biopanning and recovery of the
strongly bound phage particles, each peptide ligand is identified
by DNA sequencing and then synthesised5. Efforts in active
targeting with drug carriers decorated with synthetically pro-
duced phage-derived peptides, however, is met with varying levels
of success3,4. One example is the filamentous phage fd clones
displaying the 15-amino acid peptide GYRPVHNIRGHWAPG
(herein as GYR peptide) on its minor coat protein (p3), which
shows high binding specificity to human brain capillary endo-
thelial hCMEC/D3 cells and the mouse brain endothelium
in vivo8. On the other hand, liposomes bearing the linear form of
GYR show weak target engagement regardless of the peptide
density on liposome surfaces11. Numerous factors such as particle
shape, possible changes to peptide structure and orientation
during functionalization as well as ligand masking by plasma/
serum proteins may explain these discrepancies3,4,11–14. In
addition to these, a different peptide arrangement in the phage
microenvironment5,15,16 may account for these discrepancies and
simply grafting a synthetic phage peptide to drug carriers may not
necessarily simulate those architectural display at the bacter-
iophage tip that confer target recognition and specificity. Indeed,
the filamentous phage fd has five copies of the p3 protein on its
surface and in close proximity to each other5. Interdomain
interactions and disulfide bridges within the p3 protein can
influence p3 organisation, which in turn may promote inter-
molecular bonding among adjacent display peptides to form a
multivalent domain with high target binding avidity15–17. This
hypothesis might be applicable to the GYR peptide, where adjacent
GYR peptides on p3 scaffolds could potentially interact with each
other through arginine (R)-mediated bidentate hydrogen bonding,
non-covalent π stacking between neighbouring aromatic indole
side-chain of tryptophan (W) and imidazole of histidine (H) and
salt-bridges. Thus, supramolecular forms of GYR, rather than in
monomeric state, may confer improve target recognition. We test
this hypothesis by directing GYR self-assembly into core-shell
nanoparticles and multiple crossed β-sheet nanofibrils [thereafter as
NanoLigand Carriers (NLCs)]. NLCs target at least two receptors
on cerebral endothelial cells, cross the blood-brain-barrier (BBB) on
intravenous injection and deliver functional nucleic acids into the
brain without adverse reactions and toxicity. Thus, hierarchical
forms of a brain-specific phage peptide overcome specificity lim-
itations in active targeting and crossing of the BBB with conven-
tional nanoparticles11,18,19.
Results
Peptide synthesis and self-assembly. We performed a two-step
chemical modification at the N-terminal of GYR to initiate self-
assembly. First, we added a cysteine (C) amino acid to promote
cross-linking (via disulfide bridge formation) between two adja-
cent peptides. Next, we linked a fluorophore (5-carboxy-fluor-
escein, 5-FAM, or cyanine 5.5, Cy5.5) to the amino group of C to
initiate π–π stacking among conjugates. Fluorophore introduction
also allows for qualitative monitoring and quantification of pep-
tide uptake by cells and in vivo tracing. The fluorescent
amphiphile-peptide conjugate, termed FAM-CGY (Table 1), was
synthesised by a standard solid-phase method, purified by semi-
preparative reverse-phase high performance liquid chromato-
graphy and characterised by analytical HPLC and mass spectro-
metry (Supplementary Fig. 1). FAM-CGY exhibited a molecular
mass of 2075.24 g mol−1, a critical aggregation concentration
(CAC) of 2.8 µM in Milli-Q water (Supplementary Fig. 2) and a
β-sheet structure at concentrations above CAC (Supplementary
Fig. 3). At concentrations below CAC, FAM-CGY (and CGY)
displayed a random coil conformation (Supplementary Fig. 3).
For comparison, we synthesised and characterised a number of
FAM (or Cy5.5)-tagged analogues (Table 1, Supplementary
Figs. 4–10). SDS-PAGE analysis revealed the presence of FAM-
CGY monomer and dimer below the CAC, but oligomers were
additionally present above the CAC (Fig. 1a). When tris(2-
chloroethyly) phosphate (which reduces C to free thiol) was
present, FAM-CGY did not form oligomers (Fig. 1b). Similarly,
FAM-GYR (the analogue without C) did not form any detectable
oligomers (Fig. 1c). On the other hand, in the absence of fluor-
ophore, CGY only formed dimers (Fig. 1d). These observations
suggest a role for disulfide bridges in dimerisation and
fluorophore-mediated π–π stacking in oligomerisation processes.
Re-positioning of FAM to the C-terminal, while maintaining the
C at the N-terminal [CGY-(K)-FAM] or changing the position of
arginine 10 (R10) in FAM-CGY (termed scrambled peptide 1,
SP1), or replacing the single tryptophan 13 (W13) from the
sequence with a glycine (G) (termed SP2) all prevented oligo-
merisation (Fig. 1e, f). These results further highlight the
importance of sequence specificity in peptide self-assembly/oli-
gomerisation, which may include R-mediated bidentate hydrogen
bonding, histidine (H)-mediated hydrogen-π interactions, and
additional π-π stacking contribution from the aromatic indole
side-chain of W and imidazole in H. The N-terminal introduction
of both FAM and C to a structurally irrelevant peptide of 8 amino
Table 1 Peptide and fluorophore-peptide conjugate description
Peptide Abbreviation Amino acid sequence Molecular mass (gmol−1) Purity (%)
GYR GYRPVHNIRGHWAPG Not applicable –
CGY CGYRPVHNIRGHWAPG 1820.04 98.11
FAM-CGY 5-FAM-CGYRPVHNIRGHWAPG 2178.36 98.91
CGY-(K)-FAM CGYRPVHNIRGHWAPGK-5-FAM 2305.53 98.36
FAM-GYR 5-FAM-GYRPVHNIRGHWAPG 2075.24 98.46
FAM-CGY scrambled 1 5-FAM-CGYRPVHNIGHWRAPG 2177.36 98.56
FAM-CGY scrambled 2 5-FAM-CGYRPVHNIRGHGAPG 2048.20 98.26
Cy5.5-CGY Cy5.5-CGYRPVHNIRGHWAPG 2385.30 98.20
Cy5.5-CGY scrambled 1 Cy5.5- CGYRPVHNIGHWRAPG 2385.90 98.50
Sequences are represented by one standard amino acid code symbols. 5-FAM= 5-carboxy-fluorescein and Cy5.5= cyanine 5.5
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Fig. 1 FAM-CGY assemblies and their characterisation. a Non-reducing SDS-PAGE of FAM-CGY at different concentrations showing oligomer formation at
>5 µM. b SDS-PAGE of FAM-CGY in the presence of tris(2-chloroethyl) phosphate (TCP), which reduces cysteine to free thiol and prevents FAM-CGY dimer
and oligomer formation. c–f SDS-PAGE analysis of FAM-GYR, CGY and other analogues, showing absence of oligomers. Peptide sequences are depicted in
Table 1. Molecular weight markers are shown in each gel (last lane in a and e and first lane in other gels). g Representative topographic atomic force
microscopy images of FAM-CGY assemblies. The image shows the presence of both nanoparticles and fibre-like structures (white threads). h Representative
electron micrographs of FAM-CGY assemblies showing the presence of electron dense nanoparticles and branched-fibres. iMagnified electron micrograph of
a typical nanoparticle, where tightly packed protofilament projections forms the shell. j Shows a nanoparticle with surface projected fibres. k, l Representative
magnified views of twisted nanofibres. m A typical size distribution profile of FAM-CGY NLCs as a function of particle concentration determined by
nanoparticle tracking analysis. n Calculated zeta potential values of FAM-CGY NLCs from electrophoretic mobility measurements. Each experiment was
repeated three times with different preparations of FAM-CGY (n= 3) with identical results
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acids (the NAP peptide that lacks R and H amino acids)20, which
is the smallest active element of activity-dependent neuropro-
tection protein that exhibits potent neuroprotection action, did
not induce aggregation or formation of higher structures (Sup-
plementary Fig. 11). Thus, we have demonstrated multifactorial
processes in GYR dimerisation and oligomerisation.
Characterisation. Atomic force microscopy (AFM) and trans-
mission electron microscopy (TEM) of FAM-CGY showed pre-
sence of both nanoparticles and fibre-like species (Fig. 1g, h). No
structural arrangements were detected or observed with other
analogues. The electron micrographs revealed a core-shell mor-
phology for nanoparticles (Fig. 1i). The core component is pre-
sumably an assembly of highly condensed FAM-CGY multimers
that grow further, eventually forming tightly packed protofila-
ment projections of the shell component (Fig. 1i). Occasionally,
protofilaments projections of the core-shell particles grow into
fibrils (Fig. 1j) with twisted elongated architectures (Fig. 1k, l).
These fibrils are presumably stabilised through extensive R-
mediated bidentate hydrogen bonding (due to charge delocali-
sation on guanidium group in R) as well as FAM- and aromatic
amino acid side-chain directed π–π stacking. These suggestions
are in line with reported observations that have indicated a role
for such interactive forces in forming fibres and sheets from
synthetic peptide amphiphiles21–24. Thus, the inability of the
scrambled peptides to form protofibrils and nanofibres further
highlight the critical role of 5-FAM-peptide secondary structure
(Supplementary Fig. 3) in multimer formation.
Energetically, β-sheet ribbons may be unstable, since the
hydrophobic blocks of the fluorophore and some aromatic amino
acid side-chains may be exposed to the solvent. However, twisting
of β-sheet ribbons would bury such hydrophobic domains inside,
resulting in stable fibril formation. Collectively, these arrange-
ments may contribute to amphiphile-peptide self-assembly into
cylindrical, ribbon-like, twisted single or multiple fibres (Fig. 1k,
l)21,25,26. Morphologically, these elongated structures resemble
many misfolded amyloid type protein aggregates in neurodegen-
eration, where two or more protofilaments twist repetitively
around each other27,28. SDS-PAGE studies (Fig. 1a) also suggest
FAM-CGY assemblies formed in Milli-Q water (including
nanofibres) are not SDS-stable, since they appear as monomer
through hexamer on the gels.
Next, we studied size distribution of the aforementioned NLCs
formed in Milli-Q water by Nanoparticle Tracking Analysis
(NTA). The results in Fig. 1m show a typical size distribution of
tracked species displaying a mean size of 169 ± 77 nm, with a
mode of 138 nm. The tailing portion of the size-distribution
histogram may represent dismantled fibrils, since no spherical
particles >200 nm was observed under the transmission electron
microscope. In contrast to FAM-CGY, neither CGY nor FAM-
GYR, nor scrambled peptides formed any detectable species by
NTA (or TEM) even at concentrations as high as 20 μM. Finally,
from electrophoretic mobility measurements we calculated two
zeta potential (ζ) peaks for NLCs; a major peak of +1.55 mV and
a minor peak of +37.8 mV, respectively (Fig. 1n). The higher ζ
value, presumably represent architectural arrangements with
multiple surface exposed R amino acid residues.
NLC-cell interaction. The results in Fig. 2a show concentration-
dependent association of FAM-labelled NLCs with human brain
capillary endothelial hCMEC/D3 cells. NLC association with
endothelial cells was not affected by the presence of serum pro-
teins (Supplementary Fig. 12), thus the binding specificity of
NLCs is preserved in the presence of extracellular proteins. Stu-
dies with a panel of transport inhibitors demonstrated that the
NLC uptake is energy-dependent, multifaceted and involves cla-
thrin- and caveolae-dependent endocytic processes as well as
macropinocytosis (Fig. 2b)29,30. The involvement of different
NLC internalisation pathways is consistent with the polarised
nature of endothelial cells and may suggest involvement of dif-
ferent receptors in NLC recognition30. In contrast to FAM-CGY,
the cellular uptake of FAM-GYR and other modified/scrambled
FAM-conjugated peptides was relatively low (Supplementary
Fig. 13). Collectively, the abovementioned observations suggest
that NLC binding to hCMEC/D3 cells is specific and pre-
dominantly structure-based.
Live-cell fluorescent microscopy studies confirmed NLC
internalisation (Fig. 2a) and localisation to early endosomes and
lysosomal compartments at the peri-nuclear regions (Supple-
mentary Fig. 14). However, considering a role for caveolin-
mediated internalisation30, we did not observe notable fluorescent
overlay with other organelles such as the Golgi apparatus and
endoplasmic reticulum (Supplementary Fig. 15).
The cerebral capillary endothelial cells, including the hCMEC/
D3 cell line, widely express homodimeric transferrin receptors
(TfRs)30,31 and confirmed here (Supplementary Fig. 16). First, we
investigate whether TfR plays a role in NLC recognition and
uptake, since TfR-ligand complexes undergo clathrin-dependent
endocytosis30,31. Competition studies in the presence of increas-
ing concentration of a partially iron saturated human transferrin
diminished NLC uptake by hCMEC/D3 cells at 37 °C (Fig. 2c).
The highest tested concentration of transferrin (500 nM),
however, inhibited NLC uptake by ~50% thus suggesting a role
for TfR in NLC uptake. However, this partial inhibition could be
either due to rapid TfR recycling, or higher avidity of NLCs for
TfR and/or involvement of other receptors in NLC uptake. Next,
we showed intracellular co-localisation of FAM-CGY NLCs with
Texas Red-labelled transferrin (Supplementary Fig. 17). This
provided further support for a clathrin-mediated uptake pro-
cesse30,31. Since transferrin could reduce NLC uptake by hCMEC/
D3 cells, we further studied NLC uptake following TfR down-
regulation with a TfR-specific siRNA (Fig. 2d). Using a
commercial transfectant, TfR expression in hCMEC/D3 cells
was down-regulated by 70% without inducing cell death (the cell
viability was >95% as determined by the Trypan Blue exclusion
test). This partial TfR down regulation reduced both transferrin
(positive control) and NLC uptake by hCMEC/D3 cells (Fig. 2d)
and the NLC uptake results are in line with transferrin
competition studies (Fig. 2c). Since, some NLC uptake still
proceeds, downregulation of TfR may have not impaired
endocytic efficacy of hCMEC/D3 cells. Finally, to further address
the possible role of TfR in NLC uptake, we compared NLC uptake
by two epithelial human cell lines, one with high expression of
TfR (MCF-7, a human breast cancer cell line) and the other with
poor expression of TfR (MCF-10A, a non-tumourigenic epithelial
cell line of mammary gland/breast origin, which expresses only
10% of TfR compared with MCF-7 cells). The results in Fig. 2e
show predominant NLC uptake by MCF-7 cells. To show that
NLC uptake by MCF-7 cells is TfR specific, we performed a
saturation study. The results in Fig. 2f show that saturation of TfR
binding sites with holo transferrin at 4 °C dramatically diminishes
NLC binding and clearly differentiates between NLC-specific
binding to TfR and nonspecific interactions with plasma
membrane. These observations, therefore, support the involve-
ment of TfR in NLC recognition.
Next, we considered the signal-transduction pattern recognition
receptor RAGE in NLC binding, since RAGE is widely expressed
on cerebral endothelial cells, is localised in caveolae and binds a
diverse repertoire of multiple crossed β-sheet fibril ligands
including beta-amyloid (Aβ) oligomers32–37. It is therefore
plausible that RAGE could bind to multiple crossed β-sheet
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structures in NLC nanofibres and the protofilament components
of the “core-shell” nanoparticles and direct internalisation. We
tested this hypothesis by showing a significantly less (p < 0.05;
non-paired two-sided student t-test) NLC uptake by hCMEC/D3
cells in competition with increasing concentration of a commer-
cially available RAGE ligand (Fig. 2b). Also, lowering RAGE
expression in hCMEC/D3 cells with a RAGE-specific siRNA (the
cell viability was >95% on RAGE down regulation as determined
by the Trypan Blue exclusion test) reduced NLC uptake compared
with their respective mock-silenced cells (Fig. 2g). Partial RAGE
downregulation, also reduced tetramethylrhodamine (TAMRA)-
labelled Aβ oligomer uptake by hCMEC/D3 cells, which is, at
least, consistent with oligomeric Aβ1–42 internalisation through
endocytic processes and RAGE involvement in Aβ binding
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(Fig. 2g). Considering RAGE involvement in Aβ uptake, we
further showed competition between Aβ oligomers (globular
structures of 5 nm in diameter)37,38, and NLCs on cell uptake
(Supplementary Fig. 18). However, we did not investigate as to
whether this competition is directly through RAGE binding or
could further involve other plasma membrane domains such as
lipoprotein receptor protein and N-methyl-D-aspartate receptor,
which are also known to bind Aβ39. Finally, simultaneous
presence of both transferrin and the RAGE peptide ligand blocked
NLC uptake more effectively (~70%) than any of the individual
treatments in hCMEC/D3 cells (Fig. 2c), thereby confirming TfR
and RAGE as predominant receptors in NLC uptake.
We therefore conclude that NLC uptake by brain endothelial
cells involves at least two receptors (TfR and RAGE) and consistent
with both clathrin- and caveolae-dependent modes of internalisa-
tion. Macropinocytosis, which has been implicated in the uptake of
protein aggregates by different cells40, may still account for the
uptake of various oligomeric/aggregate forms of FAM-CGY. Our
cell studies, however, could not differentiate on the mode of uptake
between spheroidal and nanofibre NLCs at this stage.
Since hCMEC/D3 cell line has been validated as a BBB
model41, we sought to examine the effect NLCs on the integrity of
this in vitro model. A hCMEC/D3 monolayer was formed and
reached confluence on day 7 and the barrier integrity was
confirmed through trans-endothelial electrical resistance (TEER)
and cell layer capacitance (which reflects the membrane surface
area) measurements with a CellZscope (Supplementary Fig. 19).
TEER values were peaked on day 7 (~40Ω cm−2) in transwell
inserts and longer culture of cells (up to 10 days) did not improve
TEER and formation of multiple cell-layers was sometime
observed from day 7 onward. Again, at day 7 the cell layer
capacitance was below 2 µF cm−2 (compared with ~10 µF cm−2
in empty inserts). Subsequently, we confirmed the expression of
adheren β-catenin, which is required for the formation of a
functional tight junction (Supplementary Fig. 19). Thereafter, the
apical side of the monolayers were challenged with NLCs, free 5-
FAM and FAM-SP1 for 24 h. The data showed no detrimental
effect of NLCs on TEER and cell layer capacitance and β-catenin
distribution (Supplementary Fig. 19). This confirms preservation
of the monolayer integrity following 24 h contact with NLCs. The
data also shows NLC uptake by hCMEC/D3 monolayers as well
as transport of a fraction across the monolayer (Supplementary
Fig. 19), presumably arising from endothelial transcytosis. In
contrast, neither the fluorophor 5-FAM nor the scrambled
peptide showed notable transport across the BBB transwell
(Supplementary Fig. 19).
FAM-CGY complexion with nucleic acids. Since NLCs at phy-
siological pH are cationic (Fig. 1k), we tested whether FAM-CGY
can form complexes with nucleic acids such as siRNA and deliver
them to the cells. We show FAM-CGY can predominantly form
spherical assemblies with siRNA (Fig. 3a). The absence of
nanofibres (as demonstrated by TEM) indicates that electrostatic
interaction between siRNA and CGY could have negatively
affected fibre growth, perhaps, by reducing the frequency of R
amino acid-mediated bidentate hydrogen bonding. The results in
Fig. 3a suggest that the uptake of FAM-CGY/siRNA nanoparticles
by hCMEC/D3 cells is predominantly through TfR, since trans-
ferrin, but not the RAGE peptide, could suppress uptake. Mac-
ropinocytosis, however, may still play a role in the uptake of these
nanostructures. When we employed a TfR-specific siRNA in
nanocomplex assembly, maximum TfR downregulation was
achieved with spherical FAM-CGY/siRNA nanoparticles carrying
24 nM siRNA (corresponding to ~80% TfR down regulation) as
demonstrated by Western blot (Fig. 3b). Control experiments
with free TfR-specific siRNA and nanocomplexes with a scram-
bled siRNA did not affect TfR expression. These nano-assemblies
were superior in down-regulating TfR expression compared with
siRNA delivered with siPORT amine (a commercial transfectant).
As an alternative example, we further demonstrated down-
regulation of claudin-5 (a trans-membrane tight junction protein
highly expressed by brain endothelial cells)42, through delivery of
claudin-5-specific siRNA with FAM-CGY (Supplementary
Fig. 20).
With respect to safety, neither FAM-CGY NLCs nor FAM-
CGY/siRNA nanoparticles perturbed plasma membrane integrity
as demonstrated through measurements of extracellular levels of
lactate dehydrogenase (LDH) (Fig. 3c). In addition to this, we also
employed an integrated metabolomics approach that measures
ATP turnover and mitochondrial oxidative phosphorylation
(OXPHOS) by high-resolution real-time respirometry43. Calcula-
tions of ATP turnover, coupling efficiency of OXPHOS and
respiratory control ratio (RCR) showed no significant changes on
either FAM-CGY NLC or FAM-CGY/siRNA nanoparticle
treatment compared with control (Fig. 3d, Supplementary
Table 1). Collectively, these observations confer cell viability
and safety, since OXPHOS accounts for the majority of ATP
production in cells and mitochondrial dysfunction plays a major
role in initiation of many types of cell-death processes43,44. These
results are in stark contrast to known cytotoxicity of Aβ
oligomers37. Finally, in contrast to FAM-CGY/siRNA nanocom-
plexes, siRNA delivery with siPORT was cytotoxic, it triggered
LDH release and suppressed ATP turnover, OXPHOS and RCR
(Fig. 3c, d, Supplementary Table 1).
For silencing, siRNA must reach the cytoplasmic compartment.
Thus, the efficient and selective down regulation of TfR and
caludin-5 achieved in our experiments could be indicative of
some levels of FAM-CGY/siRNA nanoparticle dismantling in the
late endosomes with, concomitant, destabilisation of endosomal
Fig. 2 NLC-cell interaction studies. a Concentration-dependent uptake of FAM-CGY assemblies by hCMEC/D3 cells at 24 h, 37 °C. The right panel shows a
typical fluorescence microscopy and differential interference contrast (DIC) images of a live hCMEC/D3 cell post FAM-CGY (5 µM) challenge. b The effect
of internalisation inhibitors on the uptake of FAM-CGY NLC (final concentration 5 µM) and Texas Red-labelled transferrin (5 µg per well) by hCMEC/D3
cells. The results represent mean fluorescent intensity with respect to Control (no metabolic inhibitor). Open column= transferrin; grey column= FAM-
CGY. c FAM-CGY NLC (5 µM) uptake by hCMEC/D3 cells is competitively inhibited by partially iron saturated human transferrin (Tf) and a commercially
propriety RAGE peptide (RAGE P). Test column= reference FAM-CGY NLC uptake (no inhibitors) with auto-fluorescence subtracted. Other incubations
are compared with Test incubation. Bovine serum albumin (BSA) was used as an irrelevant protein. d Down-regulation of TfR in hCMEC/D3 cells with TfR-
specific siRNA reduces Tf and FAM-CGY uptake. In the right panel, open column= control siRNA treated cells and grey column= TfR siRNA treated cells.
e Comparison of TfR expression in MCF-7 and MCF-10A cells and FAM-CGY uptake. In the right panel, open column=MCF-7 cell line and grey column=
MCF-10A cell line. f Diminished NLC (final concentration 5 μM) binding to MCF-7 cells at 4 °C on saturation of TfR binding sites. au = arbitrary unit. g The
effect of RAGE downregulation in hCMEC/D3 with a RAGE-specific siRNA on TAMRA-labelled Aβ oligomer and FAM-CGY uptake. In the right panel, open
column= control siRNA treated cells and grey column= RAGE siRNA treated cells. All incubations were done in triplicate and each experiment was
repeated three times. Panels represent the mean value of three separate experiments ± s.d. and each dot indicates the mean of three technical replicates.
*p < 0.05 and **p < 0.01, non-paired two-sided student t-test compared with respective controls. Source data are available in the Source Data file
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membrane45. NTA studies support instability of FAM-CGY
assemblies at low pH values encountered in the late endosomes
(Supplementary Fig. 21). NLC dismantling may proceed in late
endosome through protonation of H amino acids (contributing to
the loss of aromatic stabilisation) and disulfide reduction46. In a
similar manner to other reported endosome destabilising cationic
peptides, cationic FAM-CGY monomers may also express an
endosome membrane destabilising property and aid siRNA
release into the cytoplasm 45.
Next, we drove a predominant nanofibre assembly formation
between FAM-CGY and siRNA. This was achieved by employing
a fluorophore labelled siRNA (Cy3-siRNA) to promote π–π
interaction with FAM. The resultant nanofibres exhibited an
average length of 297 ± 97 nm and width of 50 ± 11 nm (n= 100),
respectively (Fig. 3e). These nanofibres provided a further
opportunity to discriminate between RAGE- and TfR-
dependent uptake mechanisms. To this end, first we showed
poor uptake of free Cy3-labelled siRNA by hCMEC/D3 cells,
whereas Cy3-siRNA was successfully taken up through nanofibre
delivery (Fig. 3e). Competition studies demonstrated that the
RAGE peptide ligand, but not transferrin, block FAM-CGY/Cy3-
siRNA uptake (Fig. 3e), since cellular Cy3-siRNA levels are
comparable to incubations with free Cy3-siRNA. Therefore,
RAGE appears to play an important role in the uptake of fibrous
NLCs <400 nm and at least in complexion with nucleic acids.
This is in contrast to an earlier study37, which demonstrated that
HeLa cells and a human neuroblastoma cell line could not
internalise fibrillar Aβ1–42. These differences may be related to
considerably longer length of fibrillar Aβ1–42 (>1 µm) than NLCs
and/or differences in receptor expression/functionality among
different cells. Nevertheless, our observations may also explain
why previously described amphiphilic peptide fibres had shown
some specificity for the brain endothelium24, as the recognition
process might have been mediated through RAGE binding due to
its substrate specificity for large size multiple crossed β-sheet
assemblies.
Brain targeting with intravenously injected NLCs. For intra-
venous injection and in vivo fluorescent imaging we first used
NLCs assembled from Cy5.5-CGY. Intravenously injected NLCs
are not only cleared from the blood within the first few hours of
injection, but rapidly target the brain and observable within 15
min of injection (Fig. 4a, b). This rapid brain translocation is
conceptually consistent with active targeting dogma under sheer
flow conditions3,4. The peak brain level (after correction for the
blood content) is reached at 4 h and corresponds to 5.7% of the
injected dose. Thereafter, the results show a decline in the brain
NLC level, which may be attributed to local nanoparticle dis-
mantling and/or Cy5.5-CGY degradation. In contrast, Cy5.5-
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labelled scrambled peptide (Table 1) poorly accumulates in the
brain (Fig. 4b) thus confirming FAM-CGY specificity in brain
targeting. In contrast to our observations, the best reported active
targeting with an optimised transferrin-decorated nanoparticle
formulation (a system ascribed with high target binding avidity)
has only delivered 1% of intravenously injected dose to the brain
at 8 h post injection12.
Next, we evaluated whether nanofibres formed between FAM-
CGY and a Cy5-labelled siRNA can also target the brain and
deliver siRNA. The blood clearance profile of nanofibres mirrors
that of native NLCs (Fig. 4c). The results also show considerable
siRNA deposition to the brain (observable within an hour of
injection and peaks by 4 h), which was not achievable on injection
of naked siRNA or siRNA in combination with the FAM-labelled
1 
10 
100 
0 5 10 15 20 25 
Cy5.5-CGY 
Cy5.5-SP 
1 
10 
100 
0 5 10 15 20 25 
Cy5-siRNA 
Cy5-siRNA/FAM-CGY 
Cy5-siRNA/FAM-SP 
FAM-CGY RAGE Overlay 
FAM-CGY TfR Overlay 
FAM-CGY CD31 Overlay 
Cy5-siRNA RAGE Overlay 
TfR Overlay 
CD31 Overlay 
Cy5-siRNA 
Cy5-siRNA 
Bl
oo
d 
le
ve
l (%
 of
 in
jec
ted
 do
se
) 
Bl
oo
d 
le
ve
l (%
 of
 in
jec
ted
 do
se
) 
Br
ai
n 
le
ve
l (%
 of
 in
jec
ted
 do
se
) 
Br
ai
n 
le
ve
l (%
 of
 in
jec
ted
 do
se
) 
Time (h) 
Time (h) 
Time (h) 
Time (h) 
0 h 
1 h 
4 h 
Cy
5-
siR
NA
 
Cy
5-
siR
NA
/F
AM
-S
P 
Cy
5-
siR
NA
/F
AM
-C
G
Y 
0.0 
2.0 
4.0 
6.0 
8.0 
0 5 10 15 20 25 
Cy5-siRNA 
Cy5-siRNA/FAM-CGY 
Cy5-siRNA/FAM-SP 
0.0 
2.0 
4.0 
6.0 
8.0 
0 5 10 15 20 25 
Cy5.5-CGY 
Cy5.5-SP 
a b 
c d 
e 
f g 
Cy5-Channel Overlay FAM-Channel 
N
ak
ed
  
Cy
5-
siR
NA
 
Cy
5-
siR
NA
/
FA
M
-C
G
Y 
Cy
5-
siR
NA
/
FA
M
-S
P 
FA
M
-C
G
Y 
N
LC
s 
Cy
5-
siR
NA
/F
AM
-C
G
Y 
CC 
CC 
CC 
Hc
* 
* 
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12554-2
8 NATURE COMMUNICATIONS |         (2019) 10:4635 | https://doi.org/10.1038/s41467-019-12554-2 | www.nature.com/naturecommunications
scrambled peptide (Fig. 4d). Again, the kinetics of siRNA
accumulation in the brain parallels that of native NLCs, thus
suggesting siRNA delivery is mediated by FAM-CGY. Quantita-
tively, these results correspond to peak brain siRNA level of 4.03
pmoles at 4 h post injection of FAM-CGY/Cy5-labelled siRNA
complexes compared with 0.84 pmole in the case of naked Cy5-
siRNA. Naked siRNA is subjected to rapid renal, and to some
extent, hepatic clearance47,48. Our results further show delay in
renal clearance of Cy5-siRNA delivered through complexion with
FAM-CGY (siRNA brain to kidney ratio 1:8 and 1:59 for FAM-
CGY/Cy5-siRNA and naked siRNA injections, respectively)
(Supplementary Fig. 22).
Fluorescent microscopy of the brain sections showed the
presence of NLC fluorescent (with and without the fluorescent
siRNA cargo) in the brain parenchyma (Fig. 4e). This may be an
indicative of active uptake by cerebral endothelial cells and
transcytosis through RAGE and TfR31,49 and consistent with
in vitro studies. Accordingly, immunofluorescent brain sections
show strong FAM-CGY NLC association with CD31+ cerebral
capillary endothelial cells (Fig. 4f). Furthermore, the NLC-derived
fluorescent overlay with both TfR and RAGE in the brain
sections. Next, we investigated whether FAM-CGY/Cy5-labelled
siRNA nanofibres exclusively overlay with RAGE. Indeed, the
results not only show some overlay between Cy5-siRNA and
CD31+ endothelial cells, but also with RAGE (Fig. 4g). Here, no
overlay was observed with TfR. Therefore, these observations are
in accord with in vitro studies, which showed nanofibre uptake by
cerebral endothelial cells is predominantly through RAGE
recognition.
Since NLCs appear in the brain parenchyma we further
examined whether they could be taken up by different
parenchymal cells. The results in Fig. 5a, b show association of
both FAM-CGY and FAM-CGY/Cy5-siRNA NLCs with neurons
and microglial cells, but not with astrocytes. Neurons and
microglial cells express TfR and RAGE50,51 and NLC uptake by
these cells may have been through these receptors, but this was
not investigated. The lack of NLC uptake by astrocytes is
interesting, despite indications that astrocytes also express TfR
and RAGE50,51. The reasons for these difference remains
unknown and may be related to the extent of receptor expression
and functionality among these cells (and microenvironmental
control), but it is also plausible that trans-endothelial transport
processes may have modified NLC properties, presenting them as
substrates for neurons and microglial cells.
Next, we assessed whether NLC/siRNA complexes can exert
pharmacological activity in the brain. This was performed by
measuring extent of β-secretase 1 (BACE1) down regulation in
hippocampus following intravenous injection of FAM-CGY/β-
secretase 1 (BACE1)-specific siRNA complexes. BACE1 is highly
expressed in neurons and it is responsible for initiating Aβ
generation and therefore has been considered as an important
target for the therapeutic inhibition of Aβ production in
Alzheimer’s disease52. The results show that a single intravenous
injection of FAM-CGY/BACE1-siRNA nanoparticles down
regulates BACE1 expression by ∼50% compared with FAM-
CGY/control siRNA complexes as determined by Western blot
(Fig. 5c). Furthermore, intravenous injection of BACE1 siRNA
either in free form or with FAM-SP1 showed no pharmacological
activity in hippocampus. These observations provide a pharma-
cological proof-of-concept for functionality of a nucleic acid
medicine in the brain through NLC delivery and validate the
capability of the engineered NLCs to functional as neurological
nanomedicines.
NLC safety. We studied the effect of intravenously injected FAM-
CGY, FAM-CGY/BACE1-specific siRNA (spheroidal objects) and
FAM-CGY/Cy5-siRNA (nanofibres) NLCs on the structure of all
main organs. The haematoxylin and eosin sections of the brain
(cerebral cortex and hippocampus) show that NLC treatment
does not induce neuronal injury/swelling, cellular liquefaction,
necrosis and focal inflammatory cellular infiltration (Fig. 6a–d,
Supplementary Fig. 23). In addition to these observations, bio-
chemical analysis of brain homogenates for inflammatory mar-
kers tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β),
IL-6, ionised calcium-binding adaptor molecule 1 (Iba-1; micro-
glia marker) and glial fibrillary acid protein (GFAP; astrocyte
marker) also revealed no inflammation in response to NLC
treatment (Fig. 6e–i).
In line with the brain investigations, no adverse morphological
changes and inflammatory reactions were observable throughout
the liver and the kidneys (including renal cortex, renal corpuscle,
glomerulus, proximal convoluted tubule, juxtaglomerular appa-
ratus and renal medulla) (Supplementary Fig. 24) as well as other
major organs (heart, lungs and spleen) (Supplementary Fig. 25) at
all studied time points and the results were similar to those of
control animals. These observations are particularly important
with respect to the liver and the kidney, as these organs play a key
role in the overall NLC extraction from the blood. Furthermore,
NLC treatment had no effect on blood count (Supplementary
Table 2). As a positive control we show selected organ damage
and alterations in blood count on lipopolysaccharide injection.
Finally, NLCs did not induce complement activation in human
sera (Supplementary Fig. 26). Collectively, these observations
together with lack of FAM-CGY (with and without nucleic acids)
cytotoxicity in hCMEC/D3 cells confer NLC safety.
Fig. 4 Blood clearance and brain deposition level of intravenously injected NLCs in mice. a Blood clearance of intravenously injected Cy5.5-CGY and
Cy5.5 scrambled peptide (SP). b Brain levels of Cy5.5-CGY and its scrambled formulation after correction for the blood content of the brain. c Blood
clearance of intravenously injected Cy5-siRNA/FAM-CGY complexes compared with naked Cy5-siRNA and CY5-siRNA complexion with FAM-scrambled
peptide (SP). d Brain levels of Cy5-siRNA delivered through the aforementioned formulations in (c). The brain level of siRNA is subtracted from the organ
blood level. The right section shows animal imaging of siRNA accumulation in the head region. A typical animal image for each formulation is shown. In all
experiments the final concentration of the peptide conjugate was 10 µM and that of siRNA was 48 nM, based on blood volume calculation equivalent to 6%
of the body weight. All injections were done in groups of three animals and each experiment was repeated three times. The results are mean values ± s.d. e
Fluorescent microscopy images of brain sections (following transcardial perfusion and fixation) showing the presence of intact Cy5-siRNA/FAM-CGY in
the brain (yellow colour in overlay). f Fluorescent microscopy images of the brain sections showing the presence of FAM-CGY in the brain and co-
localisation with CD31+ endothelial cells as well as TfR and RAGE (some examples are depicted with arrows in overlay images). CC= cerebral cortex, Hc
= hippocampus and * denotes deep cerebral white matter. g Fluorescent microscopy images of the brain sections showing the presence of Cy5-siRNA
(delivered through complexion with FAM-CGY) in the brain and co-localisation with CD31 positive endothelial cells and RAGE (some examples are
depicted with arrows in overlay images), but not TfR. In both (f) and (g) NLCs appear in the brain parenchyma. Each experiment was repeated at least
three times (in three different animals) with different sections (n= 9). Scale bar= 100 μm. Source data are available in the Source Data file
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Discussion
Through simple chemical modification of the phage-derived GYR
peptide we engineered two distinct hierarchical platforms in the
form of core-shell nanoparticles and nanofibres capable of tar-
geting at least two distinct receptors (TfR and RAGE) on cerebral
capillary endothelial cells. On intravenous injection, these
platforms crossed the BBB and reached neurons and microglial
cells. Subsequently, we demonstrated siRNA delivery to the brain
and showed pharmacological activity through BACE1 silencing.
Thus, these attempts have overcome previous limitations in
active-targeting with GYR functionalised drug carriers8,11 and are
advantageous over other nano-based approaches, since it neither
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Fig. 6 Brain safety of intravenously injected NLCs and NLC-siRNA complexes. The images show haematoxylin and eosin stained sections of cerebral cortex
at 4 h, 24 h and 72 h after administration of saline (a), FAM-CGY peptide (10 μM) (b), FAM-CGY/BACE1-specific siRNA (c) and FAM-CGY/Cy5-siRNA
complexes (d). In (c) and (d) FAM-CGY and siRNA concentrations were 10 μM and 48 nM, respectively. Magnified regions of box inserts are shown.
E= cerebral endothelial cells, G= glial cells, M=microglial cells and N=Neurons. Scale bar= 100 μm. ELISA determination of pro-inflammatory markers
TNF-α (e), IL-6 (f) and IL-1β (g) in hippocampus on NLC and NLC-siRNA treatments compared with control (p > 0.05 in all cases; n= 3 determinations).
Determination of microglial marker Iba-1 (h) and astrocyte marker GFAP (i) in hippocampus on NLC treatment (p > 0.05 in all cases; n= 3
determinations). Lipopolysaccharide (LPS) injection induced a small, but significant (*p < 0.05 in all cases compared with control and NLC treatments;
n= 3 determinations) proinflammatory response at 24 h sacrifice point. All statistical analyses were performed with one-way ANOVA, using Tukey’s
multiple comparison correction to calculate significance. Source data are available in the Source Data file
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require complex design nor extensive metabolic modulation/
perturbation in the whole organism (e.g., glucose deprivation) 53.
At large, active translocation of hydrophobe-CGY/nucleic acid
complexes into the brain opens many opportunities for genetic
manipulation of the blood-brain-barrier and parenchymal cells
involved in escalation of various neurodegenerative diseases54.
Importantly, unlike intracellular Aβ37, NLCs do not induce
bioenergetics crisis and cell death and therefore are perceived as
effective and safe delivery systems (or nanotherapeutics).
In summary, we have provided a conceptual framework in
active targeting through self-assembly of a peptide ligand into
targetable nanocarriers (Fig. 7). Unlike most phage virions5,
NLCs are internalised by target cells, which presumably is a
function of their polyvalent surface patterned nature and hence
high target binding avidity. Furthermore, NLCs overcome the
lack of cell specificity in targeting with cell-penetrating peptides55.
We foresee future development of multifunctional NLCs with
broader specificities, for instance, through replacement of the
fluorophore component with other hydrophobes or drugs and/or
cross-linking of hydrophobe-CGY conjugates to pharmacological
peptides through a disulfide bridge.
Methods
Reagents. For all reagents catalogue numbers (♯number) are indicated. Human
transferrin (#10652202001), bovine serum albumin (BSA) (#A9418), pyrene
(#82648), crystal violet solution (#HT90132), (tris)2-chloroethy)phosphate (TCEP)
(#07296), 2-deoxy-D-glucose (#D8375), sodium azide (#71289), worthmanin
(#W1628), chloropromazine (#C8138), N-ethylmaleimide (#E1271), indomethacin
(#I7378) and lipopolysaccharide from Escherichia coli O55:B5 (#L2880) were
purchased from Sigma-Aldrich Co. LLC (Seelze, Germany). Texas Red®-Trans-
ferrin (#T2875), mouse anti-human transferrin receptor antibody (#A-11130),
mouse anti-β-tubulin (#32-2600), HRP-goat-anti-mouse IgG (H+L) (#62-6520),
HRP-goat-anti-rabbit IgG (H+L) (#65-6120) and Novex® ECL Chemiluminescent
Substrate Reagent Kit (#WP20005) were purchased from Life Technologies (CA,
USA). RAGE peptide (#ab32414), rabbit polyclonal to mouse and human RAGE
(#ab3611), rabbit anti-mouse and human TfR antibody (#ab84036), rabbit anti-
human claudin-5 antibody (#ab131259), anti-Tuj1 antibody (#ab78078, Abcam,
UK), anti-GFAP antibody (#ab10062), mouse monoclonal to CD31 (#ab24590,
reacts with mouse and human), rabbit polyclonal to CD31 (#ab28364, reacts with
mouse and human), rabbit polyclonal to β-catenin (#ab16051, reacts with human),
rabbit monoclonal anti-BACE1 antibody (#ab108394), donkey anti-mouse IgG
H&L (Alexa Fluor®680) (#ab175774), donkey anti-mouse IgG H&L (Alexa
Fluor®450) (#ab175658) and donkey anti-mouse IgG H&L AlexaFluor555
(#ab150110) were purchased from Abcam (Cambridge, UK). Anti-Iba1 antibody
(#ab019-19741) was from Wako, Japan. Amyloid β1–42 (Aβ) peptide (#AS-20276)
and tetramethylrhodamine (TAMRA)-labelled amyloid β1–42 peptide (#AS-60488)
were purchase from AnaSpecas (CA, USA). Goat anti-rabbit IgG (H+ L) Super-
clonal secondary antibody Alexa Fluor 555 (#A27039) was from ThermoFisher
Scientific UK. Cy3-siRNA (#AM4621), anti-TfR siRNA (#4390824, siRNA ID:
s727), anti-RAGE siRNA (#4392420, siRNA ID: s1166), anti-claudin-5 siRNA
(#4392420, siRNA ID: s14245) and siPORT Amine Transfection agent (#AM4503)
were purchased from Ambion Inc. (TX, USA). Cy5-siRNA (#siL0727105040) and
BACE1 siRNA (sense of 5′-GCUUUGUGGAGAUGGUGGATT-3′ and antisense:
5′-UCCACCAUCUCCACAAAGCTT-3′, #siB170613094224) were from Guangz-
hou RiboBio Co., Ltd. (Guangzhou, China). Western blot stripping buffer (#SC-
281698) and control siRNA (#sc-37007, sequence not disclosed by the manu-
facturer) were from Santa Cruz Biotech Inc. (CA, USA). ProteoJET™ Mammalian
Cell Lysis Reagent (#K0311) was purchased from Fermentals Life Sciences
(Ontario, Canada). Hoechest 33342 (350/461) (#H3569), CellLight® Reagents
BacMam 2.0 Early endosomes-RFP (555/584) (#C10587) and Lysosomes-RFP
(555/584) (#C10597) were purchased from Molecular Probes, Life Technologies
(CA, USA).
Cell lines and media. The human brain endothelial cell line (hCMEC/D3) was
obtained under licence from University Paris 05, CNRS, Institute Cochin, INSERM
(Paris, France). The cell line was maintained and characterised in accordance to
regularly updated protocols by Institute Cochin and certified mycoplasma free56.
Human breast cancer cell line (MCF-7) (ATCC® HTB-22™) and human mammary
epithelial cell line (MCF-10A) (ATCC® CRL-10317™) were purchased from
American Type Culture Collection (VA, USA). Endothelial Basal Medium (EBM-
2) (#CC-3156) was from Lonza Group Ltd. (Basel, Switzerland). Dulbecco/Vogt
Modified Eagle's Minimal Essential Medium (DMEM) (#D0819), basic fibroblast
growth factor (#F0291), gelatin solution (#G1393), hydrocortisone (#H-0888),
insulin (#I-1882) and phosphate buffered saline (PBS) (#D8537) were purchased
from Sigma-Aldrich Co. LLC. (Seelze, Germany). Foetal bovine serum (FBS)
(#16000044) and penicillin/streptomycin (#15140122) were obtained from Gibco-
BRL, Carlsbad Life Technologies (CA, USA). Recombinant human EGF (AF-100-
15) was from PeproTech EC Ltd. (Hamburg, Germany). HEPES (#S11-001) was
from PAA Cell Culture Company (Pasching, Austria). The cell culture flasks and
plates were purchased from Corning Inc. (NY, USA).
Elisa kits. Enzyme-linked immunosorbent assay (ELISA) kits for mouse TNF-α
(#RAB0477 Millipore), mouse IL-6 (#RAB0309), mouse IL-1β (#RAB0275) and
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Fig. 7 Schematic summary of NLC construction and active targeting of the brain. Animal images represent FAM-CGY NLC (left; corresponding to core-shell
nanoparticle morphology) and Cy5-siRNA/FAM-CGY NLC (right; corresponding to nanofibre morphology) deposition in the brain at 2 h post intravenous
injection and corresponding immunofluorescent brain sections at 4 h, showing NLC deposition in neurons and microglial cells
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GFAP (#NS830 Millipore) were supplied by Merck (USA). The ELISA kit for
quantitative detection of mouse IBA1 (#LS-F7666) was provided by Lifespan
Biosciences Inc. (WA, USA). Elisa kits for quantitative detection of human com-
plement products C3a (#A031), C5a (#A020) and sC5b-9 (#A020) were from
Quidel (CA, USA).
Peptide synthesis. Peptide synthesis (sequences as in Table 1) was carried out by a
solid-phase method as described in detail in Supplementary File (Supplementary
Fig. 1, 4–11). Peptides were purified by preparative HPLC (Shimadzu LC-8A) and
characterised by the analytical HPLC (Shimadzu LC-20AB) and mass spectroscopy
(Shimadzu LCMS2020). The lyophilized peptides were stored at −20 °C under
nitrogen atmosphere.
Self-assembly. The critical aggregation concentration of FAM-CGY was deter-
mined in Milli-Q (MQ) water using pyrene as a probe (n= 3 determinations) at
room temperature57. SDS-PAGE was carried out using XCell SurelockTM system
(Invitrogen, CA, USA) with precast 12 % NuPAGE® Bis-tris mini gels (Invitrogen,
CA, USA) operated at a constant voltage of 200 V in NuPAGE® MES running
buffer (Invitrogen, CA, USA). For non-reducing conditions, various concentrations
of the peptides were prepared by dilution of the stock solution in MQ water and
incubated for 30 min at room temperature. The NuPAGE® LDS sample buffer (4×)
(Invitrogen, CA, USA) was added to the peptide solutions and 10 µL of each
mixture solution was loaded into individual wells. For the reducing condition
TCEP was co-incubated with peptide overnight to disrupt the disulfide bonds. Gels
were stained with SilverXpress® Silver Staining Kit (Life Technologies, CA, USA)
according to the manufacture’s protocol. SDS-PAGE experiments were repeated
with three different batches of peptides and each experiment as performed at least
three times.
Circular dichroism (CD). The CD spectrum of CGY, FAM-CGY peptide (at
concentrations below and above the CAC) was measured on a Jasco J-810 spec-
tropolarimeter (Jacso Incorporated, MD, USA) with 4 s accumulations every 1 nm
and averaged over three acquisitions.
Microscopy. For AFM, a sample of 5 μM FAM-CGY (or other analogues and
complexes thereof) was applied to a cleaned mica surface and air-dried at room
temperature for 30 min. AFM was performed on a tapping mode with a com-
mercial Nanoscope IV MultiMode SPM (Veeco, Santa Barbara, USA). A 12 µm
piezoscanner (E scanner) (Veeco, Santa Barbara, USA) was employed for imaging.
For TEM, FAM-CGY (or other analogues and complexes) was negatively stained in
accordance with an established procedure. Briefly, a 10 μL sample of 5 μM FAM-
CGY (or other complexes) was placed onto a 200 mesh carbon-coated copper grids
and allowed to stand for 5 min. Excess solvent was carefully removed by capillary
action using a filter paper and the sample was immediately stained with 10 μL of
2% (v/v) phosphotungstic acid solution for 2 min. Excess stain was removed and
the grids were allowed to dry for 20 min. Images were taken with a Philips CM100
transmission electron microscope (FEI/Philips, Eindhoven, Netherland) with an
accelerating voltage of 80 kV. Nanoparticle dimensions were determined using
Image J software (http://rsb.info.nih.gov/ij/download.html) and reported as the
mean size of at least 100 randomly selected images ± s.d.
Nanoparticle Tracking Analysis (NTA). NTA measurements were performed
with a NanoSight LM20 (NanoSight, Amesbury, United Kingdom) equipped with a
sample chamber with a 405 nm blue laser and a Viton fluoroelastomer O-ring57.
Briefly, different concentrations of peptides and complexes were prepared and
diluted appropriately before measurement. Size and particle concentration mea-
surements were performed at room temperature as well as at 37 °C. Each experi-
ment was repeated at least three times and the results are presented as mean ± s.d.
When necessary, a typical distribution profile is shown.
Zeta potential. The zeta potential of FAM-CGY and other complexes was cal-
culated from electrophoretic mobility measurements using Zetasizer Nano ZS
(Malvern, UK) at 21 °C. Each experiment was repeated at least three times and the
results are presented as mean ± s.d.
Cell culture. hCMEC/D3, MCF-7 and MCF-10A cells were grown either per
manufacturer’s instructions or following the guideline of the donated laboratory.
Briefly, hCMEC/D3 cells were grown in EBM-2 medium supplemented with 5% (v/
v) FBS, 1.4 μM hydrocortisone, 1 ng mL−1 basic fibroblast growth factor, 1% (w/v)
penicillin/streptomycin and 10 nM HEPES58. MCF-7 and MCF-10A cells were
grown in DMEM containing 10% (v/v) FBS, 1% (w/v) penicillin/streptomycin, 0.5
μg mL−1 hydrocortisone, 10 μg mL−1 insulin and 20 ng mL−1 recombinant human
EGF. All cells were maintained at 37 °C in a humidified atmosphere. Adherent cells
were harvested with 0.05% (w/v) trypsin at a sub-cultivation ratio of 1:3, while non-
adherent cells were seeded at a density of 7 × 105 cells per flask in 75-Flask and
maintained at 70–80% confluence.
Cell uptake and trafficking. Peptide internalisation was measured by flow cyto-
metry (FACS ArrayTM Cell Analysis, Becton, Dickinson and Company, NJ, USA).
Cells (1 × 105 cm−2) were seeded on 24-well plates and grown 1 day at 37 °C and
5% CO2 in order to reach 60–70% confluence. The cells were washed 3 times with
pre-heated PBS. The uptake studies were initiated by adding 500 µL of 5 µM
fluorescence-labelled peptides (diluted in cell medium containing with different
serum concentration). Serum concentration in incubation varied from 5 to 20% (v/
v). After 24 h of incubation, treated cells were then washed three times with pre-
warmed PBS and harvested by trypsinisation. A total of 10,000 cells were analysed
by flow cytometry.
Intracellular trafficking of NLCs was monitored by live-cell fluorescent
microscopy. Briefly, hCMEC/D3 cells (2 × 104 cm−2) were seeded on the 8-well
Lab-Tek chamber slides (Nunc, IL, USA) for 1 day at 37 °C and 5% CO2 to reach
60–70% confluence. CellLight® Reagents BacMam 2.0 Early endosomes-RFP, or
Lysosomes-RFP was added to cells and incubated for 24 h58. The cells were washed
three times with pre-heated PBS and the uptake studies were initiated by adding
200 µL samples of different NLCs (diluted in cell medium and incubated for 30 min
at 37 °C prior to addition). After 4 h or 24 h of incubation at 37 °C, each chamber
was washed three times with pre-heated PBS and incubated with the respective
fresh cell growth medium. The cell nucleus was stained with Hoechst 34580 dye (5
µg mL−1)58,59. Live-cell imaging was performed on a wide-field microscope (Leica
AF6000LX, Hamburg Germany) using a 63× oil objective with 1.6 magnification
and analysed with appropriate filters. Z-stacking was performed using appropriate
sectioning steps ranging from 0.2 to 0.7 µm. Diffraction PSF 3D was used to
calculate the point spread function followed by 3D deconvolution by Leica LAS AF
Lite software58,59. The co-localisation analysis was processed with Image J to
calculate Manders’ coefficient.
In some experiments, cells (2 × 104 cm−2) were treated with a range of
internalisation inhibitors at sub-cytotoxic concentrations (confirmed by Trypan
Blue exclusion tests where cell viability >95%) for 1 h at 37 °C. The medium was
then removed and replaced with a fresh medium containing NLCs and the
corresponding inhibitor. After 8 h of incubation at 37 °C, cells were washed three
times with cell medium and analysed by FACS. Cell viability at the end of each
experiment was >90% as determined by Trypan Blue exclusion test. The
following inhibitors were used: 2-deoxy-D-glucose (1 mM)/sodium azide (1
mM) as energy-dependent inhibitors, worthmanin (10 μM) as macropinocytosis
inhibitor, chloropromazine (30 μM) as clathrin-dependent endocytosis inhibitor,
N-ethylmaleimide (5 μM) as caveolae-dependent endocytosis and transcytosis
inhibitor and indomethacin (200 μM) as caveolae-dependent endocytosis
inhibitor.
Competition studies. In competition experiments, 5 µM NLCs were co-incubated
with different concentrations of transferrin or RAGE peptide or amyloid β1–42
oligomers in hCMEC/D3 cells for 16 h. The amyloid β1–42 oligomers were prepared
using a previous method60. BSA was used as control protein competitor. The
fluorescence microscopy and FACS were employed to observe and quantify FAM-
CGY self-assembly uptake, respectively.
In some experiments, MCF-7 cells (5 × 105 per well) were incubated in
Dulbecco’s phosphate buffered saline (DPBS) supplemented with 1% w/w BSA and
0.1% (w/w) sodium azide for 30 min at 4 °C. Then after, incubations were
continued for a further 1 h with increasing concentrations of holo transferrin. Next,
cells were washed three times with DPBS and then incubated with 5 μM FAM-CGY
NLCs in DPBS [supplemented with 1% (w/w) BSA and 0.1% (w/w) sodium azide]
for 1 h at 4 °C. Finally, cells were washed three times and resuspended in ice cold
cell media for FACS analysis.
Silencing. hCMEC/D3 cells were transfected with anti-TfR siRNA [sense sequence
(5′-GGUCAUCAGGAUUGCCUAAtt-3′) and antisense sequence (5′-UUAGGCA
AUCCUGAUGACCga-3′)] or anti-RAGE siRNA [sense sequence (5′-GGUGGAA
CCGUAACCUGAtt-3′) and antisense sequence 5′-UCAGGGUUACGGUUCCAC
Cag-3′] or control siRNA using siPORT Amine transfection agent, according to the
manufacturer’ Neofection protocol. Briefly, siPORT Amine transfection reagent (7
µL) was added to serum-free cell medium to a final volume of 100 µL and vortexed.
Next, 70 pmol siRNA in 100 µL serum-free cell medium was added dropwise to the
diluted siPORT Amine transfection reagent. The mixture was gently mixed and
incubated at room temperature for 20 min. The transfection agent/siRNA complex
was added to culture plates containing 2.3 × 105 hCMEC/D3 cells in 2.3 mL normal
growth medium. The final concentration of siRNA was 28 nM. After 24 h incu-
bation, the medium containing transfection agent/siRNA complex was removed
and fresh growth medium was added. After 48 h post transfection, the level of
target protein (TfR or RAGE) was determined by Western blotting. The hCMEC/
D3 cells that were transfected with anti-TfR siRNA or anti-RAGE siRNA or control
siRNA for 72 h, were washed with PBS three times and then incubated with 5 µM
FAM-CGY nano-assemblies, 62.5 nM Texas Red-labelled transferrin (TfR sub-
strate) and TAMRA-labelled amyloid β1–42 (RAGE substrate). After 16 h of incu-
bation at 37 °C, cells were washed three times with pre-warmed PBS and analysed
by fluorescence microscopy. Uptake was quantified by measuring fluorescence
using FACS.
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Receptor expression. Transferrin receptor and RAGE expression level in human
cells was determined by Western blot analysis. Briefly, cells were seeded in 75 cm2-
flasks and grown to reach 60–70% confluence. The cells were washed in ice-cold
PBS three times and then scraped off the flask and collected by centrifugation. The
pelleted cells were lysed for 10 min at room temperature on a shaker (900 rpm)
following the ProteoJET™ Mammalian Cell Lysis Reagent protocol. Lysates were
spun in a centrifuge at 18,000 × g for 15 min and the supernatant was collected.
Equal protein aliquots were resolved by SDS-PAGE, transferred to nitrocellulose
membranes using iBot Dry Blotting system (Invitrogen, CA, USA), immunoblotted
with primary antibodies (mouse anti-human TfR antibody or rabbit polyclonal to
mouse and human RAGE) (1;200 and 1:750, respectively) and detected with HRP-
Goat-anti-mouse (or rabbit) IgG (H+ L) secondary antibody (1:3000). Tubulin
was immunoblotted with mouse anti-human-β-tubulin (1:200) and detected with
HRP-Goat-anti-mouse IgG (H+ L) secondary antibody (1:3000). These were fol-
lowed by incubation with Novex® ECL Chemiluminescent Substrate Reagent Kit.
The Bands were quantified with ImageJ 1.44p (http://imagej.nih.gov/ij/).
FAM-CGY/siRNA assemblies. Peptide/siRNA assemblies were formed by drop-
wise addition (80–240 nM range) of either Cy3-siRNA or functional anti-TfR
siRNA or anti-Claudin-5 siRNA (with the sense and antisense sequences of 5′-
CCUUAACAGACGGAAUGAAtt-3′ and 5′-UUCAUUCCGUCUGUUAAGGgc-
3′) to 50 µM FAM-CGY in physiological saline and incubated for 30 min. Next, the
mixtures were diluted with saline to a final peptide concentration 5 µM for TEM
studies. In vitro uptake and silencing experiments were performed in hCMEC/D3
cells. Briefly, peptide/siRNA nano-assemblies (5 µM FAM-CGY and either 8 or 16
or 24 nM functional siRNA, final concentration) were added to 2.3 × 105 hCMEC/
D3 cells. After 24 h incubation, the medium was replaced by fresh growth medium.
After another 48 h of incubation, the level of the target protein was determined by
Western blotting. The results were compared with parallel experiments containing
nano-assemblies formed from FAM-CGY and an irrelevant siRNA as well as
transfection procedures with complexes formed between siRNA and siPORT
Amine transfection agent. Cy3-siRNA uptake was quantified by measuring median
cell fluorescence using FACS.
Cell functionality and viability. LDH release was followed at 24 h post transfec-
tion procedures. The measurement was performed using CytoTox96® Non-
Radioactive Cytotoxicity Assay kit (Promega, WI, USA)43. The maximum amount
of LDH in the cells, induced by the addition of a lysis solution, was measured and
used as a 100% LDH release and compared with peptidoplex and siPORT-siRNA
complex-induced LDH release as well as to spontaneous cellular LDH release
(untreated cells). To investigate the possible adverse effects of transfectants on cell
respiration, hCMEC/D3 cells were seeded in XF96 V3 cell culture microplates
(Seahorse Bioscience, CA, USA) at 1.0 × 104 cells per well in growth medium. The
day after, cells were incubated with designated concentrations of transfectants at
37 °C and 5% CO2 for 24 h. Following incubation, medium was replaced with
serum and bicarbonate free assay medium (Seahorse Bioscience, CA, USA) 30 min
before monitoring the oxygen consumption rate (OCR) in real-time using XF96
Analyzer (Seahorse Bioscience CA, USA)43,61. Different respiratory states were
analysed in order to calculate the coupling efficiency of OXPHOS and the mito-
chondrial RCR43,61. Data was corrected for any possible effect of difference in cell
numbers41,56. Cell numbers were evaluated by growing XF96 V3 cell culture
microplate in parallel and following incubation with designated concentrations of
transfectants. Cells were fixed with 11% (v/v) glyceraldehyde and stained with
crystal violet. Crystal violet was then extracted with 10% (v/v) acetic acid and the
absorbance measured at λ= 595 nm. Standard curve was made to demonstrate the
linear relationship between cell numbers and crystal violet staining and for
obtaining accurate cell numbers. The real-time OCR was thereafter normalised for
cell numbers using the absorbance values 43,61.
Transwell studies. For the construction of the in vitro BBB model, hCMEC/D3
cells were seeded on rat tail collagen-coated polycarbonate membranes (Transwell,
No. 3401 Costar; Corning, Wiesbaden, Germany; 0.4 μm pore size; 1.13 cm2
growth area) with a density of 100,000 cells cm−2. Every three days the cell medium
was change. In general after 7 days growth, the cells reached confluence. The
transendothelial electrical resistance (TEER) and cell layer capacitance (CCL),
which reflects the membrane surface area of the hCMEC/D3 cell monolayer, were
measured using CellZscope system (NanoAnalytics, Münster, Germany). Cells with
CCL values in the range of 0.5–5.0 μF cm−2 indicate cell confluence and validate
TEER values were selected for the transfer experiments. NLCs at different con-
centrations were introduced in to the apical side of the BBB model. The TEER
values were measured during the incubation. After 24 h of incubation, the media
from basal and apical sides were sampled and analysed for fluorescent measure-
ment. CD31 and paracellular adherens (β-catenin) junctions were assessed by
immunofluorescence labeling directly on the cell monolayer attached to the
transwell membrane. Briefly, cells were fixed by 4% v/v paraformaldehyde for 10
min, rinsed and then permeabilised with 0.5% (v/v) Triton X-100 for 10 min. After
rinsing samples were blocked by 5% w/v BSA for 1 h, followed by incubation with
primary antibodies (rabbit polyclonal to CD31, rabbit polyclonal to anti-β-catenin)
in 1% w/v BSA overnight at 4 °C. Next, samples were rinsed and incubated with
10 µg mL−1 secondary antibody (Alexa Fluor® 555 goat anti-rabbit IgG, Life
Technologies, Eugene, OR, USA) in 1% (w/v) BSA for 1 h. After rinsing, the red
fluorescence from tight junction proteins was observed by a Leica AF6000LX
microscope equipped with a 63 × objective using ×1.6 magnifications.
Statistical analysis. All cell studies were done in triplicate incubations and each
experiment was repeated at least 3 times. The results are presented as mean ± s.d.
Statistical analysis and comparison of different groups in relation to one or two
factors were performed with one-way ANOVA or two-way ANOVA as appro-
priate. The Bonferroni method was subsequently used to correct p values after
multiple comparisons to calculate statistical significance, otherwise stated.
Complement activation. NLC-mediated (final concentration of either 1 or 5 μM in
serum) complement activation was performed in fresh human sera through ELISA
determination of fluid phase C3a, C5a and sC5b-9 in human sera using respective
Quidel kits (San Diego, CA, USA)62. Activation products did not adhere to FAM-
CGY NLCs. Functional assessment of complement pathways were in accordance
with manufacturer’s specifications 62,63.
Compliance. Animal protocols were in accordance with the guidelines and reg-
ulations of “Animal Care and Use Committee Guidelines of Guangzhou Institute of
Biomedicine and Health”, approved and performed at Guangzhou Institute of
Biomedicine and Health, China.
Animal experiments. Groups of male and females (50:50 distribution) ICR mice
(6–8 weeks old, body weight 20–26 g) were randomly selected (n= 3 per group)
and injected with Cy5.5-CGY NLCs, Cy5.5-CGY scramble peptide, Cy5-siRNA/
FAM-CGY complexes, or Cy5-siRNA/FAM-CGY scramble peptide complexes via
tail vein. The final concentration of the peptide conjugate was 10 µM and that of
siRNA was 48 nM based on blood volume calculation equivalent to 6% of the body
weight. At different time points blood samples were collected via retro-orbital
blood collection. For whole animal imaging system mice were anaesthetised with
isoflurane and in vivo fluorescence images were taken (IVIS 200 Spectrum, USA),
at different time points. At 4 h post administration, mice were sacrificed, and the
liver, lungs, kidneys, spleen, pancreas and brain were collected and stored in liquid
nitrogen. The organs were homogenised (FastPrep-24™ 5G Instrument, MP Bio-
medicals, USA) and the levels of peptide and siRNA were measured in a fluores-
cence spectrometer (Fluotime 300, Picoquant, Berlin, Germany) using a
standard curve.
In some experiments, animals were transcardially perfused with 10 mL 0.9% (w/
v) saline at a rate of 2 mLmin−1 through the left ventricle to remove the blood
from the brain, followed by 20 mL 4% (v/v) paraformaldehyde in phosphate
buffered saline (PBS, pH= 7.4). The brain was removed and post-fixed overnight
in 4% (v/v) paraformaldehyde followed by dehydration with 30% (w/v) sucrose
solution in PBS at 4 °C. Frozen sections were cut on a cryostat (Thermo fisher,
USA). The 10 μm thick brain sections were treated with 1% (w/v) BSA in PBS/0.1%
(w/v) Tween 20 for 30 min, and stained with primary anti-RAGE (1:150 dilution),
anti-Transferrin receptor (1:200 dilution), and anti-CD31 (1:400 dilution)
antibodies individually overnight at 4 °C. Secondary antibodies were donkey anti-
mouse Alexa Fluor®680 (1:1000 dilution) (in animals that received FAM-CGY
NLCs; applicable to Fig. 4f) and donkey anti-mouse Alexa Fluor®405 (1:1000
dilution) (in animals that received Cy5-siRNA/FAM-CGY complexes; applicable to
Fig. 4g) for microscopy detection. To visualise neurons, microglial and astrocytes,
sections were first stained with antibodies against Tuj1 (1:500), Iba1 (1:300) and
GFAP (1:300), respectively, and then with donkey anti-mouse Alexa Fluor®555
(1:1000 dilution) secondary antibody. DAPI staining was performed to visualise
cell nuclei.
For in vivo BACE1 silencing, 20 ICR mice were randomly divided into five
groups (4 mice in each group) and administrated intravenously with either 72 nM
siControl/FAM-CGY or BACE1 siRNA (final concentration, 72 nM) or 72 nM
siControl/FAM-CGY scramble peptide1 or 48 nM BACE1 siRNA/FAM-CGY or
72 nM BACE1 siRNA/FAM-CGY, respectively. The final concentration of peptide
was 10 μM. After 48 h, mice were sacrificed and perfused with 10 mL 0.9% (w/v)
saline at a rate of 2 mLmin−1 and brain was removed. The frozen brain tissues
(80–90 mg) were homogenized in RIPA lysis buffer (Beyotime, China) and
centrifuged at 18,000 × g, 4 °C for 15 min. Protein concentration of the supernatant
was determined using the BCA Protein Assay Kit. Equal amounts of protein from
each sample were loaded on SDS-PAGE gels (4–15%) for the determination with
level of the target protein determined by Western blotting using the anti-BACE1
antibody (1:1000 dilution) and detected with HRP-Goat-anti-rabbit) IgG (H+ L)
secondary antibody (1:3000).
Safety studies in animals. The ICR mice were injected with FAM-CGY,
BACE1 siRNA/FAM-CGY and Cy5-siRNA/FAM-CGY complex via tail vein with
final peptide concentration of 10 µM and siRNA of 48 nM based on calculation of
6% of body weight for blood volume in mice. After 4, 24 and 72 h post injection,
mice were sacrificed and perfused with 10 mL 0.9% (w/v) saline at a rate of 2 mL
min−1. Organs (brain, heart, liver, lung, kidney, spleen) were collected for
haematoxylin-eosin (H&E) analysis. Tissues were sectioned at a 5 mm thickness.
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H&E staining was done by submersion in Harris hematoxylin followed by differ-
entiation through 37% HCl and Li2CO3 solution. An Olympus optical microscope
(Tokyo, Japan) was used for assessing slides. In some experiments animals received
an intravenous injection of 200 μg kg−1 lipopolysaccharide and sacrificed at 24 h
post injection for histological and blood count analysis.
Blood samples were collected for determination of red blood cell count, white
blood cell count, haemoglobin, haematocrit, mean corpuscular volume, mean
corpuscular haemoglobin, mean corpuscular haemoglobin concentration and
platelet count (XFA6030, Perlong Medical Inc., China). Hippocampus was
dissected out, rinsed in ice-cold PBS thoroughly, weighted and immediately frozen
in liquid nitrogen. Tissues were cut into small pieces and homogenized in 1 mL ice-
cold PBS with a glass homogeniser and sonicated with an ultrasonic cell disrupter
to break the cell membranes. Homogenates were centrifuges for 5 min at 5,000 × g
and supernatants were assayed immediately for quantitative determination of TNF-
α, IL-6, IL-1β, Iba-1 and GFAP by corresponding ELISA kits, respectively in
accordance with manufacturer’s instructions.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Raw data supporting peptide synthesis and characterisation, uncropped original SDS-
PAGE gels (Fig. 1) and Western blots for BACE1 determinations in brain samples and
TfR expression in human cells are reported in Supplementary Information file. Raw data
for Figs. 2–6 is provided as the Source Data file. All other raw data supporting the
findings of this study are available from the corresponding authors upon reasonable
request.
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